RU2518098C2 - Пиримидинзамещенные производные пурина, фармацевтическая композиция на их основе, способ ингибирования протеинкиназ, способ лечения или профилактики заболеваний, чувствительных к ингибированию протеинкиназ и способ лечения пролиферативных заболеваний - Google Patents

Info

Publication number

RU2518098C2

RU2518098C2 RU2010117737/04A RU2010117737A RU2518098C2 RU 2518098 C2 RU2518098 C2 RU 2518098C2 RU 2010117737/04 A RU2010117737/04 A RU 2010117737/04A RU 2010117737 A RU2010117737 A RU 2010117737A RU 2518098 C2 RU2518098 C2 RU 2518098C2

Authority

RU

Russia

Prior art keywords

group

optionally substituted

alkyl

compound according

protein kinase

Prior art date

2007-10-05

Links

• Espacenet
• Global Dossier
• Discuss

• -1 Pyrimidine-substituted purine Chemical class 0.000 title claims abstract description 132
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 56
• 201000010099 disease Diseases 0.000 title claims abstract description 51
• 230000002062 proliferating effect Effects 0.000 title claims abstract description 13
• 238000000034 method Methods 0.000 title claims description 41
• 102000001253 Protein Kinase Human genes 0.000 title claims description 38
• 108060006633 protein kinase Proteins 0.000 title claims description 38
• 230000005764 inhibitory process Effects 0.000 title claims description 21
• 239000008194 pharmaceutical composition Substances 0.000 title claims description 8
• 229940083251 peripheral vasodilators purine derivative Drugs 0.000 title 1
• 150000001875 compounds Chemical class 0.000 claims abstract description 182
• 102000038030 PI3Ks Human genes 0.000 claims abstract description 74
• 108091007960 PI3Ks Proteins 0.000 claims abstract description 74
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 64
• 201000011510 cancer Diseases 0.000 claims abstract description 47
• 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims abstract description 46
• 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims abstract description 46
• 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 42
• 230000000694 effects Effects 0.000 claims abstract description 24
• 150000003839 salts Chemical class 0.000 claims abstract description 23
• 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 22
• 125000002252 acyl group Chemical group 0.000 claims abstract description 11
• 229910052717 sulfur Inorganic materials 0.000 claims abstract description 11
• 125000004429 atom Chemical group 0.000 claims abstract description 10
• 229910052760 oxygen Inorganic materials 0.000 claims abstract description 10
• 125000004122 cyclic group Chemical group 0.000 claims abstract description 9
• 229910052736 halogen Inorganic materials 0.000 claims abstract description 9
• 150000002367 halogens Chemical class 0.000 claims abstract description 9
• 125000005842 heteroatom Chemical group 0.000 claims abstract description 8
• 150000001204 N-oxides Chemical class 0.000 claims abstract description 5
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims abstract description 3
• 125000000896 monocarboxylic acid group Chemical group 0.000 claims abstract 2
• 125000000217 alkyl group Chemical group 0.000 claims description 69
• 125000003118 aryl group Chemical group 0.000 claims description 63
• 239000012634 fragment Substances 0.000 claims description 55
• 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 42
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 36
• 125000001424 substituent group Chemical group 0.000 claims description 29
• 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 claims description 26
• 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 claims description 26
• 239000002904 solvent Substances 0.000 claims description 24
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 23
• 125000003545 alkoxy group Chemical group 0.000 claims description 18
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 16
• 229910052799 carbon Inorganic materials 0.000 claims description 14
• 229910052731 fluorine Inorganic materials 0.000 claims description 14
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 12
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 11
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 10
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
• 241000124008 Mammalia Species 0.000 claims description 8
• 230000001363 autoimmune Effects 0.000 claims description 8
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
• 208000024891 symptom Diseases 0.000 claims description 8
• 208000027866 inflammatory disease Diseases 0.000 claims description 7
• 230000002401 inhibitory effect Effects 0.000 claims description 7
• 230000007170 pathology Effects 0.000 claims description 7
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 6
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 6
• 206010029113 Neovascularisation Diseases 0.000 claims description 5
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
• 206010020718 hyperplasia Diseases 0.000 claims description 5
• 208000023275 Autoimmune disease Diseases 0.000 claims description 4
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
• 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
• 208000006994 Precancerous Conditions Diseases 0.000 claims description 3
• 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims 1
• 239000003814 drug Substances 0.000 abstract description 18
• 239000003795 chemical substances by application Substances 0.000 abstract description 10
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract description 8
• 239000000126 substance Substances 0.000 abstract description 7
• 208000035475 disorder Diseases 0.000 abstract description 5
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract description 4
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract description 3
• 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 abstract description 2
• CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 58
• 125000005647 linker group Chemical group 0.000 description 58
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 53
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
• 238000006243 chemical reaction Methods 0.000 description 43
• 125000001072 heteroaryl group Chemical group 0.000 description 36
• 210000004027 cell Anatomy 0.000 description 35
• 125000004404 heteroalkyl group Chemical group 0.000 description 31
• 108091000080 Phosphotransferase Proteins 0.000 description 29
• 239000000203 mixture Substances 0.000 description 29
• 102000020233 phosphotransferase Human genes 0.000 description 29
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 28
• 239000000243 solution Substances 0.000 description 28
• 108091008611 Protein Kinase B Proteins 0.000 description 25
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 24
• 230000015572 biosynthetic process Effects 0.000 description 22
• 238000003786 synthesis reaction Methods 0.000 description 22
• 238000011282 treatment Methods 0.000 description 22
• 208000032839 leukemia Diseases 0.000 description 19
• 239000000651 prodrug Substances 0.000 description 19
• 229940002612 prodrug Drugs 0.000 description 19
• 125000003342 alkenyl group Chemical group 0.000 description 18
• 125000004366 heterocycloalkenyl group Chemical group 0.000 description 18
• 125000000392 cycloalkenyl group Chemical group 0.000 description 17
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 17
• 229960002930 sirolimus Drugs 0.000 description 17
• 206010014599 encephalitis Diseases 0.000 description 16
• 125000004432 carbon atom Chemical group C* 0.000 description 15
• 239000011541 reaction mixture Substances 0.000 description 15
• 229940079593 drug Drugs 0.000 description 14
• 210000000056 organ Anatomy 0.000 description 14
• 208000011580 syndromic disease Diseases 0.000 description 14
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 13
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
• 229910052794 bromium Inorganic materials 0.000 description 13
• 239000000460 chlorine Substances 0.000 description 13
• 208000026310 Breast neoplasm Diseases 0.000 description 12
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 12
• 229910052801 chlorine Inorganic materials 0.000 description 12
• 125000006710 (C2-C12) alkenyl group Chemical group 0.000 description 11
• 238000005160 1H NMR spectroscopy Methods 0.000 description 11
• 101001024630 Drosophila melanogaster RNA cytidine acetyltransferase Proteins 0.000 description 11
• 101000652705 Drosophila melanogaster Transcription initiation factor TFIID subunit 4 Proteins 0.000 description 11
• 101000873927 Homo sapiens Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 description 11
• 101000996915 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Nucleoporin NSP1 Proteins 0.000 description 11
• 230000004913 activation Effects 0.000 description 11
• 230000037361 pathway Effects 0.000 description 11
• 125000006711 (C2-C12) alkynyl group Chemical group 0.000 description 10
• 206010006187 Breast cancer Diseases 0.000 description 10
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
• 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 description 10
• 125000004104 aryloxy group Chemical group 0.000 description 10
• 230000000903 blocking effect Effects 0.000 description 10
• 238000001727 in vivo Methods 0.000 description 10
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 9
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
• 125000003302 alkenyloxy group Chemical group 0.000 description 9
• 125000003282 alkyl amino group Chemical group 0.000 description 9
• 125000005133 alkynyloxy group Chemical group 0.000 description 9
• 230000000259 anti-tumor effect Effects 0.000 description 9
• 125000005553 heteroaryloxy group Chemical group 0.000 description 9
• 125000004430 oxygen atom Chemical group O* 0.000 description 9
• 208000008443 pancreatic carcinoma Diseases 0.000 description 9
• 230000026731 phosphorylation Effects 0.000 description 9
• 238000006366 phosphorylation reaction Methods 0.000 description 9
• 230000011664 signaling Effects 0.000 description 9
• 201000004624 Dermatitis Diseases 0.000 description 8
• 102000004190 Enzymes Human genes 0.000 description 8
• 108090000790 Enzymes Proteins 0.000 description 8
• HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 8
• 241000699670 Mus sp. Species 0.000 description 8
• 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 8
• 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 8
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 8
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
• 208000007502 anemia Diseases 0.000 description 8
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
• 125000004465 cycloalkenyloxy group Chemical group 0.000 description 8
• 125000000000 cycloalkoxy group Chemical group 0.000 description 8
• 235000019441 ethanol Nutrition 0.000 description 8
• 125000001188 haloalkyl group Chemical group 0.000 description 8
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
• 239000010410 layer Substances 0.000 description 8
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 8
• 239000003921 oil Substances 0.000 description 8
• 235000019198 oils Nutrition 0.000 description 8
• 201000002528 pancreatic cancer Diseases 0.000 description 8
• 239000007787 solid Substances 0.000 description 8
• 206010009944 Colon cancer Diseases 0.000 description 7
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 7
• 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 7
• 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 7
• 102000001708 Protein Isoforms Human genes 0.000 description 7
• 108010029485 Protein Isoforms Proteins 0.000 description 7
• CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 7
• 125000000304 alkynyl group Chemical group 0.000 description 7
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
• 239000003153 chemical reaction reagent Substances 0.000 description 7
• 230000001419 dependent effect Effects 0.000 description 7
• 229960005167 everolimus Drugs 0.000 description 7
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
• 229940124302 mTOR inhibitor Drugs 0.000 description 7
• 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 7
• OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 7
• 230000035772 mutation Effects 0.000 description 7
• 239000001301 oxygen Substances 0.000 description 7
• 230000008569 process Effects 0.000 description 7
• 125000006239 protecting group Chemical group 0.000 description 7
• 108090000623 proteins and genes Proteins 0.000 description 7
• 230000001105 regulatory effect Effects 0.000 description 7
• 229960000235 temsirolimus Drugs 0.000 description 7
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
• RMFWVOLULURGJI-UHFFFAOYSA-N 2,6-dichloro-7h-purine Chemical compound ClC1=NC(Cl)=C2NC=NC2=N1 RMFWVOLULURGJI-UHFFFAOYSA-N 0.000 description 6
• 206010003571 Astrocytoma Diseases 0.000 description 6
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
• 206010061535 Ovarian neoplasm Diseases 0.000 description 6
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 206010060862 Prostate cancer Diseases 0.000 description 6
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 6
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
• 208000006593 Urologic Neoplasms Diseases 0.000 description 6
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 6
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 6
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 6
• 239000002253 acid Substances 0.000 description 6
• 125000004183 alkoxy alkyl group Chemical group 0.000 description 6
• 125000004103 aminoalkyl group Chemical group 0.000 description 6
• 125000003710 aryl alkyl group Chemical group 0.000 description 6
• 238000009739 binding Methods 0.000 description 6
• 230000027455 binding Effects 0.000 description 6
• 230000004071 biological effect Effects 0.000 description 6
• 230000010261 cell growth Effects 0.000 description 6
• 239000003937 drug carrier Substances 0.000 description 6
• 208000005017 glioblastoma Diseases 0.000 description 6
• 125000004446 heteroarylalkyl group Chemical group 0.000 description 6
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 6
• 238000000338 in vitro Methods 0.000 description 6
• 229910052740 iodine Inorganic materials 0.000 description 6
• 150000002632 lipids Chemical class 0.000 description 6
• 201000001441 melanoma Diseases 0.000 description 6
• 150000003916 phosphatidylinositol 3,4,5-trisphosphates Chemical class 0.000 description 6
• 238000002360 preparation method Methods 0.000 description 6
• 125000006413 ring segment Chemical group 0.000 description 6
• 125000004434 sulfur atom Chemical group 0.000 description 6
• 238000004809 thin layer chromatography Methods 0.000 description 6
• 231100000419 toxicity Toxicity 0.000 description 6
• 230000001988 toxicity Effects 0.000 description 6
• 230000014616 translation Effects 0.000 description 6
• 210000004881 tumor cell Anatomy 0.000 description 6
• LCNUCBDNJHKSGS-UHFFFAOYSA-N 5-(9-butan-2-yl-2-chloropurin-6-yl)pyrimidin-2-amine Chemical compound N1=C(Cl)N=C2N(C(C)CC)C=NC2=C1C1=CN=C(N)N=C1 LCNUCBDNJHKSGS-UHFFFAOYSA-N 0.000 description 5
• 208000008839 Kidney Neoplasms Diseases 0.000 description 5
• 206010025323 Lymphomas Diseases 0.000 description 5
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 5
• 238000005481 NMR spectroscopy Methods 0.000 description 5
• 206010033128 Ovarian cancer Diseases 0.000 description 5
• 201000004681 Psoriasis Diseases 0.000 description 5
• 206010038389 Renal cancer Diseases 0.000 description 5
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
• 125000004442 acylamino group Chemical group 0.000 description 5
• 125000004390 alkyl sulfonyl group Chemical group 0.000 description 5
• 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 5
• 239000007864 aqueous solution Substances 0.000 description 5
• 125000004391 aryl sulfonyl group Chemical group 0.000 description 5
• 230000037396 body weight Effects 0.000 description 5
• 230000004663 cell proliferation Effects 0.000 description 5
• 208000029742 colonic neoplasm Diseases 0.000 description 5
• 125000000623 heterocyclic group Chemical group 0.000 description 5
• 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 5
• 201000010982 kidney cancer Diseases 0.000 description 5
• 125000002950 monocyclic group Chemical group 0.000 description 5
• 125000004433 nitrogen atom Chemical group N* 0.000 description 5
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 5
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
• 230000004962 physiological condition Effects 0.000 description 5
• 125000003367 polycyclic group Chemical group 0.000 description 5
• 229920001223 polyethylene glycol Polymers 0.000 description 5
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
• 239000000047 product Substances 0.000 description 5
• 102000004169 proteins and genes Human genes 0.000 description 5
• 150000003212 purines Chemical class 0.000 description 5
• 239000002994 raw material Substances 0.000 description 5
• 230000019491 signal transduction Effects 0.000 description 5
• 239000007858 starting material Substances 0.000 description 5
• 239000000758 substrate Substances 0.000 description 5
• 230000004083 survival effect Effects 0.000 description 5
• TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 4
• CGCSTMCZMMIPLE-UHFFFAOYSA-N 5-(9-butan-2-yl-2-morpholin-4-ylpurin-6-yl)pyrimidin-2-amine Chemical compound N1=C2N(C(C)CC)C=NC2=C(C=2C=NC(N)=NC=2)N=C1N1CCOCC1 CGCSTMCZMMIPLE-UHFFFAOYSA-N 0.000 description 4
• NMVPJWLFADIXCB-UHFFFAOYSA-N 5-[2-chloro-9-(3-methylphenyl)purin-6-yl]pyrimidin-2-amine Chemical compound CC1=CC=CC(N2C3=NC(Cl)=NC(=C3N=C2)C=2C=NC(N)=NC=2)=C1 NMVPJWLFADIXCB-UHFFFAOYSA-N 0.000 description 4
• XSJKEBIPLOCMKU-UHFFFAOYSA-N 5-[2-chloro-9-[(2,6-difluorophenyl)methyl]purin-6-yl]pyrimidin-2-amine Chemical compound C1=NC(N)=NC=C1C1=NC(Cl)=NC2=C1N=CN2CC1=C(F)C=CC=C1F XSJKEBIPLOCMKU-UHFFFAOYSA-N 0.000 description 4
• 208000003174 Brain Neoplasms Diseases 0.000 description 4
• 0 CC(CC1)C*1*=C Chemical compound CC(CC1)C*1*=C 0.000 description 4
• 206010008342 Cervix carcinoma Diseases 0.000 description 4
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 4
• ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 4
• 208000007766 Kaposi sarcoma Diseases 0.000 description 4
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
• 208000000172 Medulloblastoma Diseases 0.000 description 4
• 241001465754 Metazoa Species 0.000 description 4
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
• 239000012828 PI3K inhibitor Substances 0.000 description 4
• 206010039796 Seborrhoeic keratosis Diseases 0.000 description 4
• 208000000453 Skin Neoplasms Diseases 0.000 description 4
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
• 208000001106 Takayasu Arteritis Diseases 0.000 description 4
• 208000024313 Testicular Neoplasms Diseases 0.000 description 4
• 206010057644 Testis cancer Diseases 0.000 description 4
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
• 238000010521 absorption reaction Methods 0.000 description 4
• 125000001931 aliphatic group Chemical group 0.000 description 4
• 125000004644 alkyl sulfinyl group Chemical group 0.000 description 4
• 238000004458 analytical method Methods 0.000 description 4
• 125000005018 aryl alkenyl group Chemical group 0.000 description 4
• 125000001769 aryl amino group Chemical group 0.000 description 4
• 208000006673 asthma Diseases 0.000 description 4
• 208000010668 atopic eczema Diseases 0.000 description 4
• 230000003197 catalytic effect Effects 0.000 description 4
• 201000010881 cervical cancer Diseases 0.000 description 4
• 238000004587 chromatography analysis Methods 0.000 description 4
• 230000001684 chronic effect Effects 0.000 description 4
• 238000000576 coating method Methods 0.000 description 4
• 239000012043 crude product Substances 0.000 description 4
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 4
• 230000003831 deregulation Effects 0.000 description 4
• 201000001981 dermatomyositis Diseases 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• 238000000605 extraction Methods 0.000 description 4
• 201000010175 gallbladder cancer Diseases 0.000 description 4
• 239000003102 growth factor Substances 0.000 description 4
• 125000000262 haloalkenyl group Chemical group 0.000 description 4
• 125000000232 haloalkynyl group Chemical group 0.000 description 4
• 201000005787 hematologic cancer Diseases 0.000 description 4
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 4
• 238000004128 high performance liquid chromatography Methods 0.000 description 4
• 230000007062 hydrolysis Effects 0.000 description 4
• 238000006460 hydrolysis reaction Methods 0.000 description 4
• 239000003112 inhibitor Substances 0.000 description 4
• 206010023332 keratitis Diseases 0.000 description 4
• 229940043355 kinase inhibitor Drugs 0.000 description 4
• 201000007270 liver cancer Diseases 0.000 description 4
• 208000014018 liver neoplasm Diseases 0.000 description 4
• 201000005202 lung cancer Diseases 0.000 description 4
• 208000020816 lung neoplasm Diseases 0.000 description 4
• 230000003211 malignant effect Effects 0.000 description 4
• 230000004048 modification Effects 0.000 description 4
• 238000012986 modification Methods 0.000 description 4
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
• 201000001119 neuropathy Diseases 0.000 description 4
• 208000033808 peripheral neuropathy Diseases 0.000 description 4
• 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 4
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 4
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
• 239000002244 precipitate Substances 0.000 description 4
• CRTBNOWPBHJICM-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1.C1=CN=CC=N1 CRTBNOWPBHJICM-UHFFFAOYSA-N 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 230000004044 response Effects 0.000 description 4
• 239000000741 silica gel Substances 0.000 description 4
• 229910002027 silica gel Inorganic materials 0.000 description 4
• 201000000849 skin cancer Diseases 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 239000003826 tablet Substances 0.000 description 4
• 201000003120 testicular cancer Diseases 0.000 description 4
• 238000012360 testing method Methods 0.000 description 4
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
• 125000006508 2,6-difluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C(F)=C1[H])C([H])([H])* 0.000 description 3
• ANOIMIGGQRWORP-UHFFFAOYSA-N 5-(8-bromo-9-butan-2-yl-2-morpholin-4-ylpurin-6-yl)pyrimidin-2-amine Chemical compound N1=C2N(C(C)CC)C(Br)=NC2=C(C=2C=NC(N)=NC=2)N=C1N1CCOCC1 ANOIMIGGQRWORP-UHFFFAOYSA-N 0.000 description 3
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
• BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 3
• 206010000830 Acute leukaemia Diseases 0.000 description 3
• 208000003950 B-cell lymphoma Diseases 0.000 description 3
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
• 206010005003 Bladder cancer Diseases 0.000 description 3
• 206010006143 Brain stem glioma Diseases 0.000 description 3
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
• 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 3
• 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 3
• 101000795659 Homo sapiens Tuberin Proteins 0.000 description 3
• 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 3
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
• 206010020649 Hyperkeratosis Diseases 0.000 description 3
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
• 208000001126 Keratosis Diseases 0.000 description 3
• 206010023774 Large cell lung cancer Diseases 0.000 description 3
• 108010034057 Mechanistic Target of Rapamycin Complex 2 Proteins 0.000 description 3
• 102000009308 Mechanistic Target of Rapamycin Complex 2 Human genes 0.000 description 3
• 206010027406 Mesothelioma Diseases 0.000 description 3
• 208000023178 Musculoskeletal disease Diseases 0.000 description 3
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
• 206010028561 Myeloid metaplasia Diseases 0.000 description 3
• 208000014767 Myeloproliferative disease Diseases 0.000 description 3
• 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 3
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 3
• 206010029260 Neuroblastoma Diseases 0.000 description 3
• 201000010133 Oligodendroglioma Diseases 0.000 description 3
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
• 206010035226 Plasma cell myeloma Diseases 0.000 description 3
• 208000008601 Polycythemia Diseases 0.000 description 3
• 208000037062 Polyps Diseases 0.000 description 3
• 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
• 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 3
• 201000000582 Retinoblastoma Diseases 0.000 description 3
• 206010041067 Small cell lung cancer Diseases 0.000 description 3
• 208000005718 Stomach Neoplasms Diseases 0.000 description 3
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
• 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 3
• 206010052779 Transplant rejections Diseases 0.000 description 3
• 102100031638 Tuberin Human genes 0.000 description 3
• 208000025865 Ulcer Diseases 0.000 description 3
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
• 206010047741 Vulval cancer Diseases 0.000 description 3
• 208000004354 Vulvar Neoplasms Diseases 0.000 description 3
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 201000011186 acute T cell leukemia Diseases 0.000 description 3
• 230000001154 acute effect Effects 0.000 description 3
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
• 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 3
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
• 230000002491 angiogenic effect Effects 0.000 description 3
• 125000002102 aryl alkyloxo group Chemical group 0.000 description 3
• 230000009286 beneficial effect Effects 0.000 description 3
• XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
• 125000002619 bicyclic group Chemical group 0.000 description 3
• 230000033228 biological regulation Effects 0.000 description 3
• 201000008275 breast carcinoma Diseases 0.000 description 3
• BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
• 208000035269 cancer or benign tumor Diseases 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
• 230000005754 cellular signaling Effects 0.000 description 3
• 230000000875 corresponding effect Effects 0.000 description 3
• 125000005356 cycloalkylalkenyl group Chemical group 0.000 description 3
• VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 239000012636 effector Substances 0.000 description 3
• 239000003995 emulsifying agent Substances 0.000 description 3
• 201000006828 endometrial hyperplasia Diseases 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 208000030533 eye disease Diseases 0.000 description 3
• 238000001914 filtration Methods 0.000 description 3
• 238000003818 flash chromatography Methods 0.000 description 3
• 206010017758 gastric cancer Diseases 0.000 description 3
• 235000011187 glycerol Nutrition 0.000 description 3
• 125000005843 halogen group Chemical group 0.000 description 3
• 125000004447 heteroarylalkenyl group Chemical group 0.000 description 3
• 230000003463 hyperproliferative effect Effects 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 208000026278 immune system disease Diseases 0.000 description 3
• 201000005264 laryngeal carcinoma Diseases 0.000 description 3
• 201000010260 leiomyoma Diseases 0.000 description 3
• 201000005296 lung carcinoma Diseases 0.000 description 3
• 201000009546 lung large cell carcinoma Diseases 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 206010027191 meningioma Diseases 0.000 description 3
• 230000037353 metabolic pathway Effects 0.000 description 3
• 230000004060 metabolic process Effects 0.000 description 3
• 201000000050 myeloid neoplasm Diseases 0.000 description 3
• 201000011216 nasopharynx carcinoma Diseases 0.000 description 3
• 230000006548 oncogenic transformation Effects 0.000 description 3
• 150000007524 organic acids Chemical class 0.000 description 3
• 239000012074 organic phase Substances 0.000 description 3
• 201000008968 osteosarcoma Diseases 0.000 description 3
• 230000001575 pathological effect Effects 0.000 description 3
• 210000003899 penis Anatomy 0.000 description 3
• 239000006187 pill Substances 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 208000003476 primary myelofibrosis Diseases 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• 230000002035 prolonged effect Effects 0.000 description 3
• 238000011321 prophylaxis Methods 0.000 description 3
• 102000016914 ras Proteins Human genes 0.000 description 3
• 108010014186 ras Proteins Proteins 0.000 description 3
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 3
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 3
• 208000037803 restenosis Diseases 0.000 description 3
• 208000000587 small cell lung carcinoma Diseases 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 229910000029 sodium carbonate Inorganic materials 0.000 description 3
• 229910052938 sodium sulfate Inorganic materials 0.000 description 3
• 235000011152 sodium sulphate Nutrition 0.000 description 3
• 239000007909 solid dosage form Substances 0.000 description 3
• 206010041823 squamous cell carcinoma Diseases 0.000 description 3
• 201000011549 stomach cancer Diseases 0.000 description 3
• 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 3
• 239000011593 sulfur Substances 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 230000001225 therapeutic effect Effects 0.000 description 3
• 206010043554 thrombocytopenia Diseases 0.000 description 3
• 238000013518 transcription Methods 0.000 description 3
• 230000035897 transcription Effects 0.000 description 3
• 238000013519 translation Methods 0.000 description 3
• 201000005112 urinary bladder cancer Diseases 0.000 description 3
• 206010046885 vaginal cancer Diseases 0.000 description 3
• 208000013139 vaginal neoplasm Diseases 0.000 description 3
• 201000005102 vulva cancer Diseases 0.000 description 3
• 239000000080 wetting agent Substances 0.000 description 3
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• 125000004641 (C1-C12) haloalkyl group Chemical group 0.000 description 2
• 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 2
• FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical group C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
• VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 2
• PNPIODMPDCGVOY-UHFFFAOYSA-N 2,6-dichloro-9-(3-methylphenyl)purine Chemical compound CC1=CC=CC(N2C3=NC(Cl)=NC(Cl)=C3N=C2)=C1 PNPIODMPDCGVOY-UHFFFAOYSA-N 0.000 description 2
• XDLJIIILKATPAQ-UHFFFAOYSA-N 2,8-dichloro-7h-purine Chemical group ClC1=NC=C2NC(Cl)=NC2=N1 XDLJIIILKATPAQ-UHFFFAOYSA-N 0.000 description 2
• 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 2
• 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
• 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
• ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
• 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 2
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
• NRDPEAYCIFBSSJ-UHFFFAOYSA-N 9-butan-2-yl-2,6-dichloropurine Chemical compound N1=C(Cl)N=C2N(C(C)CC)C=NC2=C1Cl NRDPEAYCIFBSSJ-UHFFFAOYSA-N 0.000 description 2
• UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
• 208000026872 Addison Disease Diseases 0.000 description 2
• 208000004804 Adenomatous Polyps Diseases 0.000 description 2
• 208000008190 Agammaglobulinemia Diseases 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• 201000010000 Agranulocytosis Diseases 0.000 description 2
• 230000007730 Akt signaling Effects 0.000 description 2
• 201000004384 Alopecia Diseases 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• 206010001935 American trypanosomiasis Diseases 0.000 description 2
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
• 208000032467 Aplastic anaemia Diseases 0.000 description 2
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 2
• 208000009137 Behcet syndrome Diseases 0.000 description 2
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
• 206010006542 Bulbar palsy Diseases 0.000 description 2
• 208000017843 C syndrome Diseases 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 208000005623 Carcinogenesis Diseases 0.000 description 2
• 208000005024 Castleman disease Diseases 0.000 description 2
• 206010008263 Cervical dysplasia Diseases 0.000 description 2
• 208000024699 Chagas disease Diseases 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
• 208000002691 Choroiditis Diseases 0.000 description 2
• 208000017667 Chronic Disease Diseases 0.000 description 2
• 206010009657 Clostridium difficile colitis Diseases 0.000 description 2
• 208000015943 Coeliac disease Diseases 0.000 description 2
• 206010009900 Colitis ulcerative Diseases 0.000 description 2
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
• 206010010741 Conjunctivitis Diseases 0.000 description 2
• 206010066968 Corneal leukoma Diseases 0.000 description 2
• 206010011258 Coxsackie myocarditis Diseases 0.000 description 2
• 208000011231 Crohn disease Diseases 0.000 description 2
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
• 206010048768 Dermatosis Diseases 0.000 description 2
• 208000021866 Dressler syndrome Diseases 0.000 description 2
• 206010058314 Dysplasia Diseases 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 206010014561 Emphysema Diseases 0.000 description 2
• 206010014759 Endometrial neoplasm Diseases 0.000 description 2
• 206010014950 Eosinophilia Diseases 0.000 description 2
• 206010014954 Eosinophilic fasciitis Diseases 0.000 description 2
• 206010053177 Epidermolysis Diseases 0.000 description 2
• 206010015218 Erythema multiforme Diseases 0.000 description 2
• 240000008187 Erythrina edulis Species 0.000 description 2
• 235000002757 Erythrina edulis Nutrition 0.000 description 2
• 208000032027 Essential Thrombocythemia Diseases 0.000 description 2
• 208000004332 Evans syndrome Diseases 0.000 description 2
• 201000006107 Familial adenomatous polyposis Diseases 0.000 description 2
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 241000206672 Gelidium Species 0.000 description 2
• 208000007465 Giant cell arteritis Diseases 0.000 description 2
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
• 208000003807 Graves Disease Diseases 0.000 description 2
• 208000015023 Graves' disease Diseases 0.000 description 2
• 102000009465 Growth Factor Receptors Human genes 0.000 description 2
• 108010009202 Growth Factor Receptors Proteins 0.000 description 2
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
• 208000001204 Hashimoto Disease Diseases 0.000 description 2
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
• 208000005100 Herpetic Keratitis Diseases 0.000 description 2
• 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 2
• 206010020751 Hypersensitivity Diseases 0.000 description 2
• 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 2
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
• 206010061216 Infarction Diseases 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
• 206010023347 Keratoacanthoma Diseases 0.000 description 2
• 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 2
• 206010024380 Leukoderma Diseases 0.000 description 2
• 208000016604 Lyme disease Diseases 0.000 description 2
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
• 206010052178 Lymphocytic lymphoma Diseases 0.000 description 2
• 208000027530 Meniere disease Diseases 0.000 description 2
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
• 241000204801 Muraenidae Species 0.000 description 2
• 208000002033 Myoclonus Diseases 0.000 description 2
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
• 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 2
• 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 description 2
• 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 2
• 241000721454 Pemphigus Species 0.000 description 2
• OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
• 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 2
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 2
• XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
• 208000000766 Pityriasis Lichenoides Diseases 0.000 description 2
• 208000021161 Plasma cell disease Diseases 0.000 description 2
• 208000021738 Plummer disease Diseases 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 208000003971 Posterior uveitis Diseases 0.000 description 2
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
• 206010036774 Proctitis Diseases 0.000 description 2
• 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 2
• 206010037128 Pseudomembranous colitis Diseases 0.000 description 2
• 208000006311 Pyoderma Diseases 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• 206010037779 Radiculopathy Diseases 0.000 description 2
• 208000033464 Reiter syndrome Diseases 0.000 description 2
• 206010039705 Scleritis Diseases 0.000 description 2
• 206010039710 Scleroderma Diseases 0.000 description 2
• 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 2
• 208000021386 Sjogren Syndrome Diseases 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 2
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
• 206010051526 Tolosa-Hunt syndrome Diseases 0.000 description 2
• 241000223109 Trypanosoma cruzi Species 0.000 description 2
• 208000026911 Tuberous sclerosis complex Diseases 0.000 description 2
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 description 2
• 208000024780 Urticaria Diseases 0.000 description 2
• 206010046905 Vaginal dysplasia Diseases 0.000 description 2
• 206010047642 Vitiligo Diseases 0.000 description 2
• 102100024148 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Human genes 0.000 description 2
• DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 2
• ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 235000010419 agar Nutrition 0.000 description 2
• 206010064930 age-related macular degeneration Diseases 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 229920000615 alginic acid Polymers 0.000 description 2
• 230000029936 alkylation Effects 0.000 description 2
• 238000005804 alkylation reaction Methods 0.000 description 2
• 125000002947 alkylene group Chemical group 0.000 description 2
• 201000009961 allergic asthma Diseases 0.000 description 2
• 208000026935 allergic disease Diseases 0.000 description 2
• 230000000172 allergic effect Effects 0.000 description 2
• 230000007815 allergy Effects 0.000 description 2
• 231100000360 alopecia Toxicity 0.000 description 2
• 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
• 230000001195 anabolic effect Effects 0.000 description 2
• 230000001772 anti-angiogenic effect Effects 0.000 description 2
• 230000006907 apoptotic process Effects 0.000 description 2
• 125000005135 aryl sulfinyl group Chemical group 0.000 description 2
• 238000003556 assay Methods 0.000 description 2
• 239000012131 assay buffer Substances 0.000 description 2
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
• 208000006424 autoimmune oophoritis Diseases 0.000 description 2
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
• 239000000440 bentonite Substances 0.000 description 2
• 229910000278 bentonite Inorganic materials 0.000 description 2
• 235000012216 bentonite Nutrition 0.000 description 2
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
• IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
• SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
• 210000003461 brachial plexus Anatomy 0.000 description 2
• 210000000481 breast Anatomy 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 230000036952 cancer formation Effects 0.000 description 2
• 231100000504 carcinogenesis Toxicity 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 230000033077 cellular process Effects 0.000 description 2
• 201000007455 central nervous system cancer Diseases 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
• 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 2
• 229940125782 compound 2 Drugs 0.000 description 2
• 230000002596 correlated effect Effects 0.000 description 2
• 238000004132 cross linking Methods 0.000 description 2
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
• 239000000824 cytostatic agent Substances 0.000 description 2
• NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
• 230000007423 decrease Effects 0.000 description 2
• 230000003210 demyelinating effect Effects 0.000 description 2
• 230000002074 deregulated effect Effects 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 125000004663 dialkyl amino group Chemical group 0.000 description 2
• 125000004986 diarylamino group Chemical group 0.000 description 2
• 125000006264 diethylaminomethyl group Chemical group [H]C([H])([H])C([H])([H])N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 2
• 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 206010013781 dry mouth Diseases 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 206010014665 endocarditis Diseases 0.000 description 2
• 208000010227 enterocolitis Diseases 0.000 description 2
• 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 2
• 125000006534 ethyl amino methyl group Chemical group [H]N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 2
• 230000003176 fibrotic effect Effects 0.000 description 2
• 239000000945 filler Substances 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 230000002496 gastric effect Effects 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 230000002949 hemolytic effect Effects 0.000 description 2
• 201000010884 herpes simplex virus keratitis Diseases 0.000 description 2
• 239000005457 ice water Substances 0.000 description 2
• 206010021198 ichthyosis Diseases 0.000 description 2
• 201000002597 ichthyosis vulgaris Diseases 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 239000007943 implant Substances 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 239000012442 inert solvent Substances 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 229910052500 inorganic mineral Inorganic materials 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 239000011630 iodine Substances 0.000 description 2
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
• 201000010666 keratoconjunctivitis Diseases 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 201000011486 lichen planus Diseases 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
• 239000008297 liquid dosage form Substances 0.000 description 2
• 206010025135 lupus erythematosus Diseases 0.000 description 2
• 208000002780 macular degeneration Diseases 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 230000010534 mechanism of action Effects 0.000 description 2
• 239000002207 metabolite Substances 0.000 description 2
• 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
• 239000011707 mineral Substances 0.000 description 2
• 239000002808 molecular sieve Substances 0.000 description 2
• 201000006417 multiple sclerosis Diseases 0.000 description 2
• 208000010125 myocardial infarction Diseases 0.000 description 2
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 230000001338 necrotic effect Effects 0.000 description 2
• 230000007823 neuropathy Effects 0.000 description 2
• 239000004006 olive oil Substances 0.000 description 2
• 235000005985 organic acids Nutrition 0.000 description 2
• ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
• MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 2
• 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 201000001245 periodontitis Diseases 0.000 description 2
• 230000000505 pernicious effect Effects 0.000 description 2
• 239000003208 petroleum Substances 0.000 description 2
• 238000009520 phase I clinical trial Methods 0.000 description 2
• RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
• 150000003905 phosphatidylinositols Chemical class 0.000 description 2
• XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
• 230000035790 physiological processes and functions Effects 0.000 description 2
• 229910000027 potassium carbonate Inorganic materials 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 201000002241 progressive bulbar palsy Diseases 0.000 description 2
• WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• 206010061928 radiculitis Diseases 0.000 description 2
• 208000002574 reactive arthritis Diseases 0.000 description 2
• 210000002345 respiratory system Anatomy 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 201000000306 sarcoidosis Diseases 0.000 description 2
• 201000003385 seborrheic keratosis Diseases 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 208000017520 skin disease Diseases 0.000 description 2
• URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
• 239000008247 solid mixture Substances 0.000 description 2
• 239000000600 sorbitol Substances 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 206010043207 temporal arteritis Diseases 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 206010043778 thyroiditis Diseases 0.000 description 2
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
• 230000004614 tumor growth Effects 0.000 description 2
• 231100000397 ulcer Toxicity 0.000 description 2
• 230000002485 urinary effect Effects 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 239000001993 wax Substances 0.000 description 2
• SVNJBEMPMKWDCO-KCHLEUMXSA-N (2s)-2-[[(2s)-3-carboxy-2-[[2-[[(2s)-5-(diaminomethylideneamino)-2-[[4-oxo-4-[[4-(4-oxo-8-phenylchromen-2-yl)morpholin-4-ium-4-yl]methoxy]butanoyl]amino]pentanoyl]amino]acetyl]amino]propanoyl]amino]-3-hydroxypropanoate Chemical compound C=1C(=O)C2=CC=CC(C=3C=CC=CC=3)=C2OC=1[N+]1(COC(=O)CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C([O-])=O)CCOCC1 SVNJBEMPMKWDCO-KCHLEUMXSA-N 0.000 description 1
• BJQCPCFFYBKRLM-UHFFFAOYSA-N (3-methylphenyl)boronic acid Chemical compound CC1=CC=CC(B(O)O)=C1 BJQCPCFFYBKRLM-UHFFFAOYSA-N 0.000 description 1
• HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
• AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical class O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
• 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
• 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 1
• CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 1
• BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
• 229940058015 1,3-butylene glycol Drugs 0.000 description 1
• FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
• GPAAEZIXSQCCES-UHFFFAOYSA-N 1-methoxy-2-(2-methoxyethoxymethoxymethoxy)ethane Chemical compound COCCOCOCOCCOC GPAAEZIXSQCCES-UHFFFAOYSA-N 0.000 description 1
• SDTORDSXCYSNTD-UHFFFAOYSA-N 1-methoxy-4-[(4-methoxyphenyl)methoxymethyl]benzene Chemical compound C1=CC(OC)=CC=C1COCC1=CC=C(OC)C=C1 SDTORDSXCYSNTD-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• CNWINRVXAYPOMW-FCNJXWMTSA-N 1-stearoyl-2-arachidonoyl-sn-glycero-3-phospho-1D-myo-inositol 4,5-biphosphate Chemical group CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O CNWINRVXAYPOMW-FCNJXWMTSA-N 0.000 description 1
• HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
• YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
• UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 1
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
• YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
• LSXJPJGBWSZHTM-UHFFFAOYSA-N 2-(bromomethyl)-1,3-difluorobenzene Chemical compound FC1=CC=CC(F)=C1CBr LSXJPJGBWSZHTM-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• RGHYDLZMTYDBDT-UHFFFAOYSA-N 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone Chemical compound O=C1N(CC)C2=NC(N)=NC(C)=C2C=C1C=1C=CNN=1 RGHYDLZMTYDBDT-UHFFFAOYSA-N 0.000 description 1
• TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
• 125000005916 2-methylpentyl group Chemical group 0.000 description 1
• 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
• PFEOZHBOMNWTJB-UHFFFAOYSA-N 3-methylpentane Chemical compound CCC(C)CC PFEOZHBOMNWTJB-UHFFFAOYSA-N 0.000 description 1
• 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
• XWRFMTICDBYTFE-UHFFFAOYSA-N 5-(2-morpholin-4-yl-9-pyrrolidin-3-ylpurin-6-yl)pyrimidin-2-amine Chemical compound C1=NC(N)=NC=C1C1=NC(N2CCOCC2)=NC2=C1N=CN2C1CNCC1 XWRFMTICDBYTFE-UHFFFAOYSA-N 0.000 description 1
• DQDIVHBAYDUZAT-UHFFFAOYSA-N 5-(9-butan-2-yl-8-methyl-2-morpholin-4-ylpurin-6-yl)pyrimidin-2-amine Chemical compound N1=C2N(C(C)CC)C(C)=NC2=C(C=2C=NC(N)=NC=2)N=C1N1CCOCC1 DQDIVHBAYDUZAT-UHFFFAOYSA-N 0.000 description 1
• IXBGEJHUPKCPBO-UHFFFAOYSA-N 5-[9-(3-methylphenyl)-2-morpholin-4-ylpurin-6-yl]pyrimidin-2-amine Chemical compound CC1=CC=CC(N2C3=NC(=NC(=C3N=C2)C=2C=NC(N)=NC=2)N2CCOCC2)=C1 IXBGEJHUPKCPBO-UHFFFAOYSA-N 0.000 description 1
• VCNGNQLPFHVODE-UHFFFAOYSA-N 5-methylthiophene-2-carboxylic acid Chemical compound CC1=CC=C(C(O)=O)S1 VCNGNQLPFHVODE-UHFFFAOYSA-N 0.000 description 1
• 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 1
• 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
• 239000005995 Aluminium silicate Substances 0.000 description 1
• 206010001889 Alveolitis Diseases 0.000 description 1
• 102000006306 Antigen Receptors Human genes 0.000 description 1
• 108010083359 Antigen Receptors Proteins 0.000 description 1
• 235000017060 Arachis glabrata Nutrition 0.000 description 1
• 244000105624 Arachis hypogaea Species 0.000 description 1
• 235000010777 Arachis hypogaea Nutrition 0.000 description 1
• 235000018262 Arachis monticola Nutrition 0.000 description 1
• 241001225321 Aspergillus fumigatus Species 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
• 206010065553 Bone marrow failure Diseases 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 208000006274 Brain Stem Neoplasms Diseases 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 description 1
• VTNQWFIFOIPTQB-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(O)C1CCN Chemical compound CC(C)(C)OC(=O)N1CCC(O)C1CCN VTNQWFIFOIPTQB-UHFFFAOYSA-N 0.000 description 1
• NPRKRWDJZRUKMT-UHFFFAOYSA-N CCCC(N(CC1)CCC1[n]1c2nc(N3CCOCC3)nc(-c3cnc(N)nc3)c2nc1)=O Chemical compound CCCC(N(CC1)CCC1[n]1c2nc(N3CCOCC3)nc(-c3cnc(N)nc3)c2nc1)=O NPRKRWDJZRUKMT-UHFFFAOYSA-N 0.000 description 1
• GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
• 241000222122 Candida albicans Species 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 206010007275 Carcinoid tumour Diseases 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 229940126639 Compound 33 Drugs 0.000 description 1
• 201000007336 Cryptococcosis Diseases 0.000 description 1
• 241000221204 Cryptococcus neoformans Species 0.000 description 1
• 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
• 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• YFPJFKYCVYXDJK-UHFFFAOYSA-N Diphenylphosphine oxide Chemical compound C=1C=CC=CC=1[P+](=O)C1=CC=CC=C1 YFPJFKYCVYXDJK-UHFFFAOYSA-N 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 208000010201 Exanthema Diseases 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 206010064571 Gene mutation Diseases 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 description 1
• 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 101000605630 Homo sapiens Phosphatidylinositol 3-kinase catalytic subunit type 3 Proteins 0.000 description 1
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
• 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
• 101000623857 Homo sapiens Serine/threonine-protein kinase mTOR Proteins 0.000 description 1
• 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
• 208000035150 Hypercholesterolemia Diseases 0.000 description 1
• 208000031226 Hyperlipidaemia Diseases 0.000 description 1
• 206010020880 Hypertrophy Diseases 0.000 description 1
• 206010062767 Hypophysitis Diseases 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 240000003183 Manihot esculenta Species 0.000 description 1
• 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 101150097381 Mtor gene Proteins 0.000 description 1
• 206010028116 Mucosal inflammation Diseases 0.000 description 1
• 201000010927 Mucositis Diseases 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• PTRMFBDHCFAMOT-UHFFFAOYSA-N Nc(nc1)ncc1-c(nc(N1CCOCC1)nc12)c1nc[n]2-c1ccccc1 Chemical compound Nc(nc1)ncc1-c(nc(N1CCOCC1)nc12)c1nc[n]2-c1ccccc1 PTRMFBDHCFAMOT-UHFFFAOYSA-N 0.000 description 1
• GJIRMDLRMXTQLN-UHFFFAOYSA-N O1CCOCC1.C[Zn]C Chemical compound O1CCOCC1.C[Zn]C GJIRMDLRMXTQLN-UHFFFAOYSA-N 0.000 description 1
• 240000007817 Olea europaea Species 0.000 description 1
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
• 101150037263 PIP2 gene Proteins 0.000 description 1
• 101150073900 PTEN gene Proteins 0.000 description 1
• QIUASFSNWYMDFS-NILGECQDSA-N PX-866 Chemical compound CC(=O)O[C@@H]1C[C@]2(C)C(=O)CC[C@H]2C2=C1[C@@]1(C)[C@@H](COC)OC(=O)\C(=C\N(CC=C)CC=C)C1=C(O)C2=O QIUASFSNWYMDFS-NILGECQDSA-N 0.000 description 1
• 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
• 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
• 102100038329 Phosphatidylinositol 3-kinase catalytic subunit type 3 Human genes 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 206010057846 Primitive neuroectodermal tumour Diseases 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
• 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
• 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
• 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
• 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
• 208000006265 Renal cell carcinoma Diseases 0.000 description 1
• 208000014139 Retinal vascular disease Diseases 0.000 description 1
• 235000004443 Ricinus communis Nutrition 0.000 description 1
• 101100262439 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UBA2 gene Proteins 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 244000000231 Sesamum indicum Species 0.000 description 1
• PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
• 244000061456 Solanum tuberosum Species 0.000 description 1
• 235000002595 Solanum tuberosum Nutrition 0.000 description 1
• SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
• 241000187391 Streptomyces hygroscopicus Species 0.000 description 1
• DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 208000005485 Thrombocytosis Diseases 0.000 description 1
• 208000000728 Thymus Neoplasms Diseases 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 108010009583 Transforming Growth Factors Proteins 0.000 description 1
• 102000009618 Transforming Growth Factors Human genes 0.000 description 1
• 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
• 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
• 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
• 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
• VFERQBCJERZPAF-UHFFFAOYSA-N [3-[6-(2-aminopyrimidin-5-yl)-2-morpholin-4-ylpurin-9-yl]pyrrolidin-1-yl]-(5-methylthiophen-2-yl)methanone Chemical compound S1C(C)=CC=C1C(=O)N1CC(N2C3=NC(=NC(=C3N=C2)C=2C=NC(N)=NC=2)N2CCOCC2)CC1 VFERQBCJERZPAF-UHFFFAOYSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 239000002250 absorbent Substances 0.000 description 1
• 230000002745 absorbent Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• UMRSVAKGZBVPKD-UHFFFAOYSA-N acetic acid;copper Chemical compound [Cu].CC(O)=O UMRSVAKGZBVPKD-UHFFFAOYSA-N 0.000 description 1
• 239000012445 acidic reagent Substances 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 208000021841 acute erythroid leukemia Diseases 0.000 description 1
• 201000002454 adrenal cortex cancer Diseases 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
• 150000001447 alkali salts Chemical class 0.000 description 1
• 150000003973 alkyl amines Chemical group 0.000 description 1
• 150000001347 alkyl bromides Chemical class 0.000 description 1
• 125000005907 alkyl ester group Chemical group 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 235000012211 aluminium silicate Nutrition 0.000 description 1
• 150000001408 amides Chemical group 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 150000001413 amino acids Chemical group 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 230000002424 anti-apoptotic effect Effects 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 230000000118 anti-neoplastic effect Effects 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• 229910052786 argon Inorganic materials 0.000 description 1
• 150000001543 aryl boronic acids Chemical class 0.000 description 1
• 238000006254 arylation reaction Methods 0.000 description 1
• 229940091771 aspergillus fumigatus Drugs 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical group CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• CYKIHIBNSFRKQP-UHFFFAOYSA-N benzo[f][1]benzothiole Chemical compound C1=CC=C2C=C(SC=C3)C3=CC2=C1 CYKIHIBNSFRKQP-UHFFFAOYSA-N 0.000 description 1
• 229960002903 benzyl benzoate Drugs 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 238000005842 biochemical reaction Methods 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 230000036760 body temperature Effects 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 235000019437 butane-1,3-diol Nutrition 0.000 description 1
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
• 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
• 235000001465 calcium Nutrition 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 229940095731 candida albicans Drugs 0.000 description 1
• 150000001721 carbon Chemical group 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 208000002458 carcinoid tumor Diseases 0.000 description 1
• 239000004359 castor oil Substances 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 230000009087 cell motility Effects 0.000 description 1
• 238000001516 cell proliferation assay Methods 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 208000025997 central nervous system neoplasm Diseases 0.000 description 1
• 229960000541 cetyl alcohol Drugs 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 239000007810 chemical reaction solvent Substances 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
• WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 239000004927 clay Substances 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 230000002301 combined effect Effects 0.000 description 1
• 229940125904 compound 1 Drugs 0.000 description 1
• 229940125851 compound 27 Drugs 0.000 description 1
• 229940125898 compound 5 Drugs 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 235000008504 concentrate Nutrition 0.000 description 1
• 230000006552 constitutive activation Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 238000012937 correction Methods 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
• 125000006622 cycloheptylmethyl group Chemical group 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• JWOSTXBESVWMJW-UHFFFAOYSA-N cyclohexyl sulfamate Chemical class NS(=O)(=O)OC1CCCCC1 JWOSTXBESVWMJW-UHFFFAOYSA-N 0.000 description 1
• 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
• 102000003675 cytokine receptors Human genes 0.000 description 1
• 108010057085 cytokine receptors Proteins 0.000 description 1
• 230000001085 cytostatic effect Effects 0.000 description 1
• 239000002254 cytotoxic agent Substances 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 1
• 229950006418 dactolisib Drugs 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 230000030609 dephosphorylation Effects 0.000 description 1
• 238000006209 dephosphorylation reaction Methods 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 150000001982 diacylglycerols Chemical class 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
• IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 230000008034 disappearance Effects 0.000 description 1
• KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 230000007783 downstream signaling Effects 0.000 description 1
• 239000008298 dragée Substances 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• 229920001971 elastomer Polymers 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 230000002357 endometrial effect Effects 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 239000002702 enteric coating Substances 0.000 description 1
• 238000009505 enteric coating Methods 0.000 description 1
• 238000006911 enzymatic reaction Methods 0.000 description 1
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
• 102000015694 estrogen receptors Human genes 0.000 description 1
• 108010038795 estrogen receptors Proteins 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
• 229940093499 ethyl acetate Drugs 0.000 description 1
• FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 201000005884 exanthem Diseases 0.000 description 1
• 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
• 210000002603 extrahepatic bile duct Anatomy 0.000 description 1
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
• 208000024519 eye neoplasm Diseases 0.000 description 1
• 206010016256 fatigue Diseases 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
• 239000003517 fume Substances 0.000 description 1
• 230000000855 fungicidal effect Effects 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 230000014509 gene expression Effects 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 235000001727 glucose Nutrition 0.000 description 1
• YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
• SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
• 230000013595 glycosylation Effects 0.000 description 1
• 238000006206 glycosylation reaction Methods 0.000 description 1
• 230000009036 growth inhibition Effects 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 208000014951 hematologic disease Diseases 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
• 125000006038 hexenyl group Chemical group 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 239000003906 humectant Substances 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 238000007327 hydrogenolysis reaction Methods 0.000 description 1
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
• 208000006575 hypertriglyceridemia Diseases 0.000 description 1
• 230000007954 hypoxia Effects 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 229940125721 immunosuppressive agent Drugs 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
• 229910052738 indium Inorganic materials 0.000 description 1
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 229910010272 inorganic material Inorganic materials 0.000 description 1
• 239000011147 inorganic material Substances 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 230000031146 intracellular signal transduction Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 230000001788 irregular Effects 0.000 description 1
• 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
• ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
• 238000000021 kinase assay Methods 0.000 description 1
• 150000003893 lactate salts Chemical class 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 201000002364 leukopenia Diseases 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 201000001037 lung lymphoma Diseases 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 150000002688 maleic acid derivatives Chemical class 0.000 description 1
• 230000007257 malfunction Effects 0.000 description 1
• 208000029559 malignant endocrine neoplasm Diseases 0.000 description 1
• 208000025854 malignant tumor of adrenal cortex Diseases 0.000 description 1
• 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
• 208000016847 malignant urinary system neoplasm Diseases 0.000 description 1
• 150000002690 malonic acid derivatives Chemical class 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000001819 mass spectrum Methods 0.000 description 1
• 108010082117 matrigel Proteins 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
• WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 1
• NSPJNIDYTSSIIY-UHFFFAOYSA-N methoxy(methoxymethoxy)methane Chemical compound COCOCOC NSPJNIDYTSSIIY-UHFFFAOYSA-N 0.000 description 1
• 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
• 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
• CPZBTYRIGVOOMI-UHFFFAOYSA-N methylsulfanyl(methylsulfanylmethoxy)methane Chemical compound CSCOCSC CPZBTYRIGVOOMI-UHFFFAOYSA-N 0.000 description 1
• 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 239000003094 microcapsule Substances 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 230000002073 mitogenetic effect Effects 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
• 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
• 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 210000003739 neck Anatomy 0.000 description 1
• 230000017095 negative regulation of cell growth Effects 0.000 description 1
• 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 239000002547 new drug Substances 0.000 description 1
• 231100000344 non-irritating Toxicity 0.000 description 1
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
• 239000012457 nonaqueous media Substances 0.000 description 1
• 239000002687 nonaqueous vehicle Substances 0.000 description 1
• 231100000065 noncytotoxic Toxicity 0.000 description 1
• 230000002020 noncytotoxic effect Effects 0.000 description 1
• 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 235000003715 nutritional status Nutrition 0.000 description 1
• 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
• 201000008106 ocular cancer Diseases 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 150000002895 organic esters Chemical class 0.000 description 1
• 239000012044 organic layer Substances 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 125000002524 organometallic group Chemical group 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 150000003891 oxalate salts Chemical class 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 235000020232 peanut Nutrition 0.000 description 1
• 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
• 239000002304 perfume Substances 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
• 238000003566 phosphorylation assay Methods 0.000 description 1
• 230000000865 phosphorylative effect Effects 0.000 description 1
• LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
• 125000005544 phthalimido group Chemical group 0.000 description 1
• LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 description 1
• 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000004574 piperidin-2-yl group Chemical group N1C(CCCC1)* 0.000 description 1
• 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
• 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
• 125000005936 piperidyl group Chemical group 0.000 description 1
• 210000003635 pituitary gland Anatomy 0.000 description 1
• 210000004180 plasmocyte Anatomy 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
• 230000001686 pro-survival effect Effects 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• 229960004063 propylene glycol Drugs 0.000 description 1
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 230000029983 protein stabilization Effects 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
• LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 1
• 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
• 125000001453 quaternary ammonium group Chemical group 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 206010037844 rash Diseases 0.000 description 1
• 102000005962 receptors Human genes 0.000 description 1
• 108020003175 receptors Proteins 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000008844 regulatory mechanism Effects 0.000 description 1
• 238000002271 resection Methods 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 210000003705 ribosome Anatomy 0.000 description 1
• 150000003873 salicylate salts Chemical class 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 150000004760 silicates Chemical class 0.000 description 1
• RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
• 235000012239 silicon dioxide Nutrition 0.000 description 1
• 208000000649 small cell carcinoma Diseases 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 239000012453 solvate Substances 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 239000003206 sterilizing agent Substances 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 208000003265 stomatitis Diseases 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 150000003890 succinate salts Chemical class 0.000 description 1
• 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 150000003892 tartrate salts Chemical class 0.000 description 1
• 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 230000002381 testicular Effects 0.000 description 1
• 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
• CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
• 125000004569 thiomorpholin-2-yl group Chemical group N1CC(SCC1)* 0.000 description 1
• 125000004570 thiomorpholin-3-yl group Chemical group N1C(CSCC1)* 0.000 description 1
• 125000004571 thiomorpholin-4-yl group Chemical group N1(CCSCC1)* 0.000 description 1
• 229930192474 thiophene Natural products 0.000 description 1
• 201000009377 thymus cancer Diseases 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 210000001519 tissue Anatomy 0.000 description 1
• 230000017423 tissue regeneration Effects 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
• 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 208000009999 tuberous sclerosis Diseases 0.000 description 1
• 201000004435 urinary system cancer Diseases 0.000 description 1
• 208000037964 urogenital cancer Diseases 0.000 description 1
• 238000003828 vacuum filtration Methods 0.000 description 1
• 210000001215 vagina Anatomy 0.000 description 1
• 238000010200 validation analysis Methods 0.000 description 1
• 210000005167 vascular cell Anatomy 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 230000006711 vascular endothelial growth factor production Effects 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 208000006542 von Hippel-Lindau disease Diseases 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1